FOREST LABORATORIES INC | 30,037 Euro | -0,171 -0,57 % | |
| WKN: 856886 ISIN: US3458381064 Ticker-Symbol: FQX | Frankfurt | 17.05.13 | 08:01 Uhr |
Branche PharmaAktienmarkt S&P 500 |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 16.05. | Forest Labs Will Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual Meeting | - | Benzinga.com | |
| 15.05. | Watch for Continued Gains in Shares of Forest Laboratories | - | SmarTrend | |
| 09.05. | Treven And Forest Labs Reach Deal To Develop TRV027 To Treat Acute Heart Failure | 42 | AFX News | |
| WASHINGTON (dpa-AFX) - Trevena Inc. and Forest Laboratories Holding Limited,
a subsidiary of Forest Laboratories Inc. (FRX), an international pharmaceutical
company, announced that they... Mehr lesen zu: Treven And Forest Labs Reach Deal To Develop TRV027 To Treat Acute Heart Failure | ||||
| 09.05. | Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure | 26 | PR Newswire | |
| KING OF PRUSSIA, Pa. and NEW YORK, May 9, 2013 /PRNewswire/ -- Trevena, Inc., (Trevena) a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled... Mehr lesen zu: Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure | ||||
| 08.05. | Forest Laboratories Crosses Above its 10-day MA | - | SmarTrend | |
| 02.05. | Almirall und Forest Laboratories geben positive Resultate der zweiten Phase-III-Studie zur Kombination von Aclidinium und Formoterol bei COPD bekannt | 106 | news aktuell | |
| Barcelona Und New York (ots/PRNewswire) -- Aclidinium/Formoterol bewirkt konsistente, statistisch signifikante Verbesserung der Lungenfunktion in zweiter Zulassungsstudie zur Wirksamkeit - Positive... Mehr lesen zu: Almirall und Forest Laboratories geben positive Resultate der zweiten Phase-III-Studie zur Kombination von Aclidinium und Formoterol bei COPD bekannt | ||||
| 02.05. | Almirall, S.A. And Forest Labs Announces Positive Results From AUGMENT/COPD | 74 | AFX News | |
| WASHINGTON (dpa-AFX) - Almirall, S.A. and Forest Laboratories Inc. (FRX)
announced positive topline results from AUGMENT/COPD, the second six-month
pivotal phase III clinical trial evaluating... Mehr lesen zu: Almirall, S.A. And Forest Labs Announces Positive Results From AUGMENT/COPD | ||||
| 02.05. | Almirall and Forest Laboratories Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol Combination in COPD | 64 | PR Newswire | |
| BARCELONA and NEW YORK, May 2, 2013 /PRNewswire/ --
Aclidinium/formoterol demonstrates consistent, statistically significant lung function improvement in the second pivotal efficacy trial
Positive... Mehr lesen zu: Almirall and Forest Laboratories Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol Combination in COPD | ||||
| 01.05. | Forest Laboratories, Almirall Announce Positive Results From AUGMENT COPD | 50 | AFX News | |
| WASHINGTON (dpa-AFX) - Drug maker Forest Laboratories, Inc. (FRX) with
Almirall, S.A., on Wednesday reported positive top-line results from AUGMENT
COPD, the company's six-month phase III... Mehr lesen zu: Forest Laboratories, Almirall Announce Positive Results From AUGMENT COPD | ||||
| 01.05. | Forest Labs (FRX), Almirall Report Positive Results from 2nd AUGMENT COPD Phase III | - | StreetInsider.com | |
| 01.05. | Forest Laboratories and Almirall Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol combination in COPD | 59 | Business Wire | |
| Aclidinium/formoterol demonstrates consistent, statistically significant lung function improvement in the second pivotal efficacy trial Positive outcomes also were seen in TDI... Mehr lesen zu: Forest Laboratories and Almirall Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol combination in COPD | ||||
| 23.04. | Forest Laboratories Management Discusses Q4 2013 Results - Earnings Call Transcript | - | Seeking Alpha | |
| 23.04. | Forest Labs' Earnings Decline | 1 | Zacks | |
| 23.04. | FOREST LABORATORIES INC - 8-K, Results of Operations and Financial Condition Financial Statements ... | - | SEC Filings | |
| 23.04. | Forest Labs Q4 Profit Plunges On Lexapro Patent Expiry; Sees Growth In FY14 | 44 | AFX News | |
| WASHINGTON (dpa-AFX) - Drug maker Forest Laboratories, Inc. (FRX) reported
Tuesday a sharp decline in fourth-quarter profit as sales were mainly hurt by
the loss of patent exclusivity for... Mehr lesen zu: Forest Labs Q4 Profit Plunges On Lexapro Patent Expiry; Sees Growth In FY14 | ||||
| 22.04. | Forest Labs Likely to Miss 4Q Earnings | - | Zacks | |
| 17.04. | Almirall und Forest Laboratories geben positive Resultate der Phase-III-Studie zur Kombination von Aclidinium und Formoterol bei COPD bekannt | 80 | news aktuell | |
| Barcelona Und New York (ots/PRNewswire) -- Die zwei Mal tägliche Verabreichung von Aclidinium/Formoterol-Kombinationen in fester Dosierung zeigt statistisch signifikante Verbesserungen bei den beiden... Mehr lesen zu: Almirall und Forest Laboratories geben positive Resultate der Phase-III-Studie zur Kombination von Aclidinium und Formoterol bei COPD bekannt | ||||
| 16.04. | Almirall, Forest Labs Announce Positive Topline Phase III Study Results for Aclidinium, Formoterol Combination in COPD | 2 | Benzinga.com | |
| 16.04. | Almirall and Forest Laboratories Announce Positive Results of a Phase III Study for Aclidinium and Formoterol Combination in COPD | 87 | PR Newswire | |
| BARCELONA and NEW YORK, April 16, 2013 /PRNewswire/ --
Aclidinium / formoterol fixed dose combinations twice daily show statistically significant improvements in the two co-primary endpoints in... Mehr lesen zu: Almirall and Forest Laboratories Announce Positive Results of a Phase III Study for Aclidinium and Formoterol Combination in COPD | ||||
| 16.04. | Forest Labs, Almirall Reveal +ive Late-stage Results For Aclidinium/Formoterol | 72 | AFX News | |
| WASHINGTON (dpa-AFX) - U.S. Drug manufacturer Forest Laboratories Inc. (FRX)
and Spanish pharmaceutical company Almirall, S.A Tuesday announced positive
results form a six month phase III... Mehr lesen zu: Forest Labs, Almirall Reveal +ive Late-stage Results For Aclidinium/Formoterol | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| GILEAD SCIENCES | 43,30 | +2,44 % | Maximieren Sie Ihren Ertrag in nur 30 Minuten! (Freenet +370% / Technotrans +100% / Gilead +120% ...) |
| NOVO NORDISK | 133,00 | -0,17 % | Novo Nordisk and Paula Deen Announce Winners of the Seeing Diabetes in a New Light' Contest |
| UCB | 44,357 | -1,92 % | UCB and IBM Collaborate to Personalize Care for Epilepsy Patients |
| CELGENE | 95,79 | -0,02 % | Celgene: Apremilast For Psoriatic Arthritis Offers Upside |
| PFIZER | 22,565 | -1,03 % | Global Vision Selected by Pfizer for Worldwide Deployment of Automated Proofreading Solutions |
